Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1979 Sep;8(3):209–217. doi: 10.1111/j.1365-2125.1979.tb01004.x

Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration

F D Juma, H J Rogers, J R Trounce
PMCID: PMC1429784  PMID: 497087

Abstract

1 Plasma cyclophosphamide levels were estimated by gas-chromatography in seven patients following intravenous and oral cyclophosphamide administration. Plasma alkylating activity was determined by the nitrobenzyl pyridine (NBP) reaction.

2 The plasma T½ after intravenous administration ranged from 5.97 to 12.37 h but after oral administration was shorter, 1.32-6.8 h. The mean total body clearance was 66.6 ml kg-1 h-1 after intravenous dosing and 93.1 ml kg-1 h-1 following oral dosing. Vdβ was 0.71 (0.10 s.d.) 1 kg-1 suggesting that cyclophosphamide is distributed largely in body water.

3 The mean hepatic extraction ratio was 0.25, indicating a modest first pass metabolism. The metabolic clearance was 3.72 1 kg-1 and the intrinsic hepatic clearance 5.17 1 kg-1.

4 The mean renal clearance was 4.8 ml kg-1 h-1 with 6.5% of the administered dose excreted unchanged in the urine suggesting tubular reabsorption of cyclophosphamide.

5 The mean T½ of plasma alkylating activity was 8.82 h, there being no significant difference following oral and intravenous administration. On average, 3.5 times the alkylating activity was produced by an oral dose of cyclophosphamide as compared to an intravenous dose. It is possible that this may reflect production of a different pattern of alkylating metabolites following cyclophosphamide administration by different routes. The clinical significance of these observations is unknown.

Full text

PDF
209

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BROCK N., HOHORST H. J. UBER DIE AKTIVIERUNG VON CYCLOPHOSPHAMID IN VIVO UND IN VITRO. Arzneimittelforschung. 1963 Dec;13:1021–1031. [PubMed] [Google Scholar]
  2. Bagley C. M., Jr, Bostick F. W., DeVita V. T., Jr Clinical pharmacology of cyclophosphamide. Cancer Res. 1973 Feb;33(2):226–233. [PubMed] [Google Scholar]
  3. Bakke J. E., Feil V. J., Fjelstul C. E., Thacker E. J. Metabolism of cyclophosphamide by sheep. J Agric Food Chem. 1972 Mar-Apr;20(2):384–388. doi: 10.1021/jf60180a054. [DOI] [PubMed] [Google Scholar]
  4. Brock N., Gross R., Hohorst H. J., Klein H. O., Schneider B. Activation of cyclophosphamide in man and animals. Cancer. 1971 Jun;27(6):1512–1529. doi: 10.1002/1097-0142(197106)27:6<1512::aid-cncr2820270636>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  5. Cohen J. L., Jao J. Y., Jusko W. J. Pharmacokinetics of cyclophosphamide in man. Br J Pharmacol. 1971 Nov;43(3):677–680. doi: 10.1111/j.1476-5381.1971.tb07199.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dvorchik B. H., Vessell E. S. Significance of error associated with use of the one-compartment formula to calculate clearance of thirty-eight drugs. Clin Pharmacol Ther. 1978 Jun;23(6):617–623. doi: 10.1002/cpt1978236617. [DOI] [PubMed] [Google Scholar]
  7. Field R. B., Gang M., Kline I., Venditti J. M., Waravdekar V. S. The effect of phenobarbital or 2-diethylaminoethyl-2,2-diphenylvalerate on the activation of cyclophosphamide in vivo. J Pharmacol Exp Ther. 1972 Feb;180(2):475–483. [PubMed] [Google Scholar]
  8. Jao J. Y., Jusko W. J., Cohen J. L. Phenobarbital effects on cyclophosphamide pharmacokinetics in man. Cancer Res. 1972 Dec;32(12):2761–2764. [PubMed] [Google Scholar]
  9. Juma F. D., Rogers H. J., Trounce J. R., Bradbrook I. D. Pharmacokinetics of intravenous cyclophosphamide in man, estimated by gas-liquid chromatography. Cancer Chemother Pharmacol. 1978;1(4):229–231. doi: 10.1007/BF00257155. [DOI] [PubMed] [Google Scholar]
  10. Lundbergh P., Strandell T. Changes in hepatic circulation at rest, during and after exercise in young males with infectious hepatitis compared with controls. Acta Med Scand. 1974 Oct;196(4):315–325. doi: 10.1111/j.0954-6820.1974.tb01017.x. [DOI] [PubMed] [Google Scholar]
  11. Mouridsen H. T., Faber O., Skovsted L. The biotransformation of cyclophosphamide in man: analysis of the variation in normal subjects. Acta Pharmacol Toxicol (Copenh) 1974 Aug;35(2):98–106. doi: 10.1111/j.1600-0773.1974.tb00729.x. [DOI] [PubMed] [Google Scholar]
  12. Mouridsen H. T., Faber O., Skovsted L. The metabolism of cyclophosphamide. Dose dependency and the effect of long-term treatment with cyclophosphamide. Cancer. 1976 Feb;37(2):665–670. doi: 10.1002/1097-0142(197602)37:2<665::aid-cncr2820370209>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  13. Struck R. F., Kirk M. C., Mellett L. B., el Dareer S., Hill D. L. Urinary metabolites of the antitumor agent cyclophosphamide. Mol Pharmacol. 1971 Sep;7(5):519–529. [PubMed] [Google Scholar]
  14. Struck R. F., Kirk M. C., Witt M. H., Laster W. R., Jr Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite. Biomed Mass Spectrom. 1975 Feb;2(1):46–52. doi: 10.1002/bms.1200020109. [DOI] [PubMed] [Google Scholar]
  15. Torkelson A. R., LaBudde J. A., Weikel J. H., Jr The metabolic fate of cyclophosphamide. Drug Metab Rev. 1974;3(1):131–165. doi: 10.3109/03602537408993740. [DOI] [PubMed] [Google Scholar]
  16. Wagner J. G. Linear pharmacokinetic models and vanishing exponential terms: implications in pharmacokinetics. J Pharmacokinet Biopharm. 1976 Oct;4(5):395–425. doi: 10.1007/BF01062829. [DOI] [PubMed] [Google Scholar]
  17. Weaver F. A., Torkelson A. R., Zygmunt W. A., Browder H. P. Tissue culture cytotoxicity assay for cyclophosphamide metabolites in rat body fluids. J Pharm Sci. 1978 Jul;67(7):1009–1012. doi: 10.1002/jps.2600670738. [DOI] [PubMed] [Google Scholar]
  18. Wilkinson G. R., Shand D. G. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975 Oct;18(4):377–390. doi: 10.1002/cpt1975184377. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES